What's Happening?
A systematic review and meta-analysis of animal studies, published between 2016 and 2025, investigated the effects of Traditional Chinese Medicine (TCM) on the microbiota in chronic inflammatory airway diseases (CIAD), including asthma and chronic obstructive
pulmonary disease (COPD). The study, which included 25 animal studies (20 in the meta-analysis), aimed to integrate evidence on microbial diversity and abundance in both airway and gut environments. Researchers hypothesized that TCM would increase alpha diversity in these microbiotas. However, after re-analysis using REML random-effects models with Hartung–Knapp adjustment, no statistically significant overall differences were found between TCM intervention groups and model groups for intestinal observed-species, Chao1, or Shannon indices, nor for airway Chao1 and Shannon indices. The study noted substantial heterogeneity across the included studies, with the direction and magnitude of estimates varying significantly. While some studies indicated that TCM-treated animals showed microbial community structures closer to healthy controls, these findings were not consistently quantifiable due to differing methodologies and metrics. The review also found no statistically significant differences when comparing TCM efficacy with Western medicine interventions on airway and gut alpha diversity.
Why It's Important?
This research is important for the U.S. healthcare landscape as it scrutinizes the scientific basis for Traditional Chinese Medicine's claims regarding microbiome modulation in chronic respiratory conditions. With a growing interest in complementary and alternative medicine, and the increasing prevalence of conditions like asthma and COPD, understanding the efficacy of various treatments is crucial. The findings suggest that while TCM may influence microbiota, the current scientific evidence from animal models does not conclusively demonstrate a statistically significant overall effect on microbial diversity. This lack of consistent, quantifiable evidence could impact research funding, regulatory considerations, and clinical recommendations for integrating TCM into mainstream U.S. medical practices for CIAD. For patients and healthcare providers, it highlights the need for more rigorous, standardized research to establish clear therapeutic mechanisms and outcomes, especially given the observed heterogeneity and methodological limitations in existing studies. The comparison with Western medicine also underscores the ongoing challenge of validating alternative therapies against established treatments.
What's Next?
Future research needs to address the significant limitations identified in this review, including small sample sizes, methodological heterogeneity, and the reliance on 16S rRNA sequencing, which limits species-level interpretations. Well-designed studies with standardized sampling, sequencing, and analytical methods are warranted to clarify the effects of TCM on the CIAD microbiota. Researchers should focus on reducing confounding variables such as modeling methods, sampling sites, sequencing platforms, and administration durations. Additionally, more consistent reporting of baseline microbiota profiles and husbandry variables in animal studies is crucial. To establish a clearer understanding of TCM's therapeutic mechanisms, future studies should also consider pooling functional metagenomic, metabolomic, host-barrier, or signaling-pathway outcomes, as changes in taxonomic relative abundance alone are insufficient to demonstrate microbial function, causality, or restoration of microbial homeostasis. This will be essential for determining if and how TCM could be effectively integrated into treatment strategies for chronic inflammatory airway diseases.
Beyond the Headlines
The findings of this meta-analysis delve into the complex interplay between traditional medicine, modern scientific validation, and the intricate world of the human microbiome. Beyond the immediate clinical implications, this study touches upon the broader challenge of integrating diverse medical traditions into evidence-based healthcare systems. The observed heterogeneity and lack of statistically significant overall effects in animal models underscore the difficulty in translating complex, multi-component traditional interventions into quantifiable biological outcomes using current scientific paradigms. This raises ethical and cultural considerations regarding how different forms of knowledge are valued and validated. It also highlights the potential for long-term shifts in research methodologies, pushing for more holistic and systems-level approaches that can capture the nuanced effects of traditional therapies. The ongoing debate about the 'gut-lung axis' and its role in chronic diseases further emphasizes the need for interdisciplinary research that bridges microbiology, immunology, and traditional medicine, ultimately aiming to develop more comprehensive and personalized treatment strategies.
